EP08.01-051 Clinical Characterization and Outcomes of Non Small Cell Lung Cancer with HER2 Alterations in the Era of Immunotherapy

Abstract

HER2-altered Non Small Cell Lung Cancer (NSCLC) is a rare subgroup (2-4%) of NSCLC. Previous studies, using small cohorts, report poor outcomes and shorter survival in HER2-altered NSCLC compared to the other subtypes of NSCLC. However, most studies were done before immunotherapy is used as the first-line therapy in stage IV NSCLC. The detailed outcomes of those patients treated under the most recent guidelines are largely unknown.